The ability of PAF/PAFR signaling to elicit robust systemic pro-inflammatory, pro-proliferative, and delayed immune-suppressive responses, which are implicated in numerous clinical situations, justified its research in cancer development. This evidence concerns the gene PCLAF and cancer.